Palomar/Gillette deal enters phase two:
This article was originally published in Clinica
Executive Summary
Palomar Medical Technologies and Gillette have embarked on the second phase of a joint effort to develop and commercialise a patented home-use, light-based hair removal device for women. Palomar, of Burlington, Massachusetts, will disclose further information on proprietary optical hair-removal technology to assist in the research and Boston-based Gillette, following an amendment to the original agreement, will provide an additional $2.1m in development funding. The financing will be spread over a nine-month extension of the development phase, which is expected to be completed by August 31 2006.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.